Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 6:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 392 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hypertension, Glaucoma, Open-Angle Clear all
Completed Phase 2 Interventional

A Phase II Study to Evaluate the Additivity of Trabodenoson to Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma

NCT01917383
View directory record Official record
Conditions
Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Interventions
Trabodenoson, Latanoprost, Timolol
Drug
Lead sponsor
Inotek Pharmaceuticals Corporation
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Bristol, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 2, 2017 · Synced Oct 14, 2026, 6:51 AM EDT
Not yet recruiting Not applicable Interventional

Comparison of Goniotomy Device Outcomes in Combined Phacoemulsification-goniotomy Surgeries

NCT07418853
View directory record Official record
Conditions
Open Angle Glaucoma (OAG), Primary Open Angle Glaucoma (POAG), Secondary Open Angle Glaucoma
Interventions
Goniotomy
Procedure
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 14, 2026, 6:51 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Safety and Efficacy of PDP-716

NCT03450629
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
Brimonidine Tartrate Ophthalmic Suspension, Brimonidine Tartrate Ophthalmic Solution
Drug
Lead sponsor
Sun Pharma Advanced Research Company Limited
Industry
Eligibility
2 Years and older
Enrollment
682 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
47
States / cities
Chandler, Arizona • Prescott, Arizona • Sun City, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2022 · Synced Oct 14, 2026, 6:51 AM EDT
Completed Phase 2Phase 3 Interventional

Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension

NCT07354516
View directory record Official record
Conditions
OAG - Open-Angle Glaucoma, OHT - Ocular Hypertension
Interventions
QLS-111-FDC, Latanoprost (0.005%)
Combination Product · Drug
Lead sponsor
Qlaris Bio, Inc.
Industry
Eligibility
12 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Largo, Florida
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 14, 2026, 6:51 AM EDT
Recruiting No phase listed Observational

iDose TR Administration in an Office-Based Surgery Setting

NCT07816692
View directory record Official record
Conditions
Open Angle Glaucoma (OAG), Ocular Hypertension (OHT)
Interventions
iDose TR (travoprost intracameral implant) 75 µg
Combination Product
Lead sponsor
Glaukos Corporation
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 14, 2026, 6:51 AM EDT
Not yet recruiting Not applicable Interventional

A Prospective Interventional Cohort Study to Evaluate the Efficacy and Safety of the AquaLumen, a Novel Filtration Procedure for the Treatment of Open Angle Glaucoma

NCT06809647
View directory record Official record
Conditions
Glaucoma Open-Angle
Interventions
Glaucoma surgery
Device
Lead sponsor
PLU Ophthalmic
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Oct 14, 2026, 6:51 AM EDT
Completed Phase 3 Interventional Results available

To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes

NCT04024072
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
Brinzolamide 1% ophthalmic suspension, Azopt 1% Ophthalmic Suspension
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
18 Years and older
Enrollment
495 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 6, 2023 · Synced Oct 14, 2026, 6:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Visior on Ocular Hemodynamics

NCT02959593
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
VISIOR video goggles
Device
Lead sponsor
Visior Technologies Ltd.
Industry
Eligibility
30 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Oct 14, 2026, 6:51 AM EDT
Withdrawn Not applicable Interventional

Effect of Negative Pressure on Pattern Electroretinography Readings

NCT04433702
View directory record Official record
Conditions
Glaucoma, Open Angle, Low Risk, Ocular Hypertension, Glaucoma Suspect
Interventions
Mercury™ Multi-Pressure Dial (MPD) Experimental Goggle, Mercury™ Multi-Pressure Dial (MPD) Placebo Goggle
Device
Lead sponsor
Vance Thompson Vision
Other
Eligibility
22 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced Oct 14, 2026, 6:51 AM EDT
Completed Phase 2 Interventional Results available

POLAT-001 Compared to Latanoprost Ophthalmic Solution in Patients With Ocular Hypertension and Open-angle Glaucoma

NCT02466399
View directory record Official record
Conditions
Glaucoma
Interventions
POLAT-001, Latanoprost ophthalmic solution
Drug
Lead sponsor
Peregrine Ophthalmic
Industry
Eligibility
18 Years to 99 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Goose Creek, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Oct 14, 2026, 6:51 AM EDT
Completed Phase 2 Interventional

Phase 2b Study Evaluating Safety and Efficacy of OTX-TP Compared to Timolol Drops in the Treatment of Subjects With Open Angle Glaucoma or Ocular Hypertension

NCT02312544
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
OTX-TP, Timolol
Drug
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Fayetteville, Arkansas
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Oct 14, 2026, 6:51 AM EDT
Completed Phase 1 Interventional

Study Evaluating the Safety and Intraocular Pressure (IOP) Lowering Response of Brimonidine Tartrate Ophthalmic Solution in Subjects With Open Angle Glaucoma or Ocular Hypertension

NCT01687426
View directory record Official record
Conditions
Glaucoma and Ocular Hypertension
Interventions
Brimonidine Tartrate 0.025%, Vehicle
Drug
Lead sponsor
Eye Therapies, LLC
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Winchester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 25, 2012 · Synced Oct 14, 2026, 6:51 AM EDT
Not listed Not applicable Interventional

Use of Nanodropper vs. Standard Eyedropper in Patients With Glaucoma and Ocular Hypertension

NCT05277870
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
Nanodropper adaptor, control
Device
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 14, 2022 · Synced Oct 14, 2026, 6:51 AM EDT
Completed Not applicable Interventional

Ocular Surface Disease Changes After iStent or iStent Inject Implantation With Phacoemulsification

NCT04452279
View directory record Official record
Conditions
Ocular Surface Disease, Glaucoma, Open-Angle
Interventions
iStent or iStent inject implantation with concomitant cataract surgery
Device
Lead sponsor
Vance Thompson Vision
Other
Eligibility
22 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Jun 30, 2020 · Synced Oct 14, 2026, 6:51 AM EDT
Completed Phase 2 Interventional

Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension).

NCT04830397
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Ocular Hypertension
Interventions
QLS-101, Timolol Maleate
Drug
Lead sponsor
Qlaris Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Albany, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 17, 2025 · Synced Oct 14, 2026, 6:51 AM EDT
Completed Phase 3 Interventional Results available

DE-117 Spectrum 5 Study

NCT03697811
View directory record Official record
Conditions
Primary Open-angle Glaucoma and Ocular Hypertension
Interventions
DE-117 Ophthalmic Solution
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
32
States / cities
Chandler, Arizona • Glendale, California • Mission Hills, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Oct 14, 2026, 6:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

RESEARCH PROTOCOL: Glaucoma Treatment Adherence and Persistence

NCT01409421
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
motivational interviewing, three phone calls to remind patients to take their eye drops
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
2
States / cities
Aurora, Colorado • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 1, 2015 · Synced Oct 14, 2026, 6:51 AM EDT
Completed Phase 2 Interventional Results available

Safety and Effects of Brimonidine Intravitreal Implant in Patients With Glaucomatous Optic Neuropathy

NCT00693485
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
400 ug Brimonidine Implant, 200 ug Brimonidine Implant, Sham (no implant)
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Artesia, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2013 · Synced Oct 14, 2026, 6:51 AM EDT
Not listed Phase 1Phase 2 Interventional

Study of the Safety and Efficacy of ATS907 in Subjects With Primary Open Angle Glaucoma (POAG) and Ocular Hypertension

NCT01520116
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Ocular Hypertension
Interventions
Stage 1 - ATS907 - Dose 1, Stage 1 - ATS907 - Dose 2, Stage 1 - ATS907 - Dose 3, Stage 1 - ATS907 - Dose 4, Stage 1 - Vehicle, Stage 2 - ATS907 - Dose A - to be selected based on Stage 1, Stage 2 - ATS907 - Dose B - to be selected based on Stage 1, Timoptic
Drug
Lead sponsor
Altheos, Inc.
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
5
States / cities
Artesia, California • Glendale, California • Saint Joseph, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2012 · Synced Oct 14, 2026, 6:51 AM EDT
Completed Phase 3 Interventional Results available

Comparison of Bimatoprost Sustained Release (SR) to Selective Laser Trabeculoplasty (SLT) in Adults With Open-Angle Glaucoma or Ocular Hypertension

NCT02507687
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
Bimatoprost SR, Sham Bimatoprost SR, Selective Laser Trabeculoplasty, Sham Selective Laser Trabeculoplasty
Drug · Procedure
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
51
States / cities
Dothan, Alabama • Glendale, Arizona • Phoenix, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated May 10, 2024 · Synced Oct 14, 2026, 6:51 AM EDT
Completed Phase 2 Interventional Results available

A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma

NCT01936389
View directory record Official record
Conditions
Exfoliation Syndrome, Ocular Hypertension, Open Angle Glaucoma
Interventions
AR-12286
Drug
Lead sponsor
Robert Ritch, MD, LLC.
Other
Eligibility
50 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 14, 2026, 6:51 AM EDT
Completed Phase 3 Interventional

A Phase IIIb Study of DuoTrav to Treat Glaucoma or Ocular Hypertension

NCT00465803
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
Travoprost 0.004%/timolol 0.5% ophthalmic solution, Travoprost ophthalmic solution, 0.004%, Timolol maleate ophthalmic solution, 0.5%
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Oct 14, 2026, 6:51 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of SPARC0912 and Reference0912 in Open Angle Glaucoma or Ocular Hypertension

NCT00947661
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
SPARC0912, Reference0912
Drug
Lead sponsor
Sun Pharma Advanced Research Company Limited
Industry
Eligibility
18 Years and older
Enrollment
578 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Oct 14, 2026, 6:51 AM EDT
Completed Phase 4 Interventional Results available

24-hour IOP-lowering Effect of Brimonidine 0.1%

NCT00457795
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
brimonidine 0.1% (Alphagan® P)
Drug
Lead sponsor
Allergan
Industry
Eligibility
40 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 24, 2011 · Synced Oct 14, 2026, 6:51 AM EDT